BioSeek

NEW YORK (GenomeWeb News) – DiscoveRx today said that it has acquired BioSeek, maker of the BioMAP platform of cell-based disease models for drug screening.
Financial terms of the deal were not disclosed.

NEW YORK (GenomeWeb News) – BioSeek today said that the US Environmental Protection Agency has extended the firm's contract to participate in the ToxCast screening program.

A research team led by scientists at proteomics firm Cellzome has developed a selective inhibitor to the PI3 kinase isoform PI3Kγ.

Cellzome will use the BioMap platform in its inflammatory disease drug discovery projects.

BioSeek will apply its BioMap predictive human disease models to screen Amylin's library.

The Japanese pharmaceutical developer has licensed the BioMap platform for drug toxicology research projects.

BioSeek will use its BioMap system to conduct screening for Ono Pharmaceuticals in its compound studies.

The acquisition will combine Asterand's tissue-based services for drug discovery with BioSeek's BioMap platform and human cell-based assays.

The firm will profile compounds for the second phase of the EPA initiative.

Pages

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.